The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer
Open accessAbstract
Purpose: Active surveillance is increasingly accepted as a treatment option for favorable-risk prostate cancer. Long-term follow-up has been lacking. In this study, we report the long-term outcome of a large active surveillance protocol in men with favorable-risk prostate cancer. Patients and Methods: In a prospective single-arm cohort study carried out at a single academic health sciences center, 993 men with favorable- or intermediate-risk prostate cancer were managed with an initial expectant approach. Intervention was offered for a prostate-specific antigen (PSA) doubling time of less than 3 years, Gleason score progression, or unequivocal clinical progression. Main outcome measures were overall and disease-specific survival, rate of treatment, and PSA failure rate in the treated patients. Results: Among the 819 survivors, the median follow-up time from the first biopsy is 6.4 years (range, 0.2 to 19.8 years). One hundred forty-nine (15%) of 993 patients died, and 844 patients are alive (censored rate, 85.0%). There were 15 deaths (1.5%) from prostate cancer. The 10- and 15-year actuarial cause-specific survival rates were 98.1% and 94.3%, respectively. An additional 13 patients (1.3%) developed metastatic disease and are alive with confirmed metastases (n = 9) or have died of other causes (n = 4). At 5, 10, and 15 years, 75.7%, 63.5%, and 55.0% of patients remained untreated and on surveillance. The cumulative hazard ratio for nonprostate-to-prostate cancer mortality was 9.2:1. Conclusion: Active surveillance for favorable-risk prostate cancer is feasible and seems safe in the 15-year time frame. In our cohort, 2.8% of patients have developed metastatic disease, and 1.5% have died of prostate cancer. This mortality rate is consistent with expected mortality in favorable-risk patients managed with initial definitive intervention.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bootstrap methods: another look at the jackknife
Efron, B. (1979) · The Annals of Statistics · doi:10.1214/aos/1176344552 · Cited by 17,602
20-Year Outcomes Following Conservative Management of Clinically Localized Prostate Cancer
Albertsen, P. C. (2005) · JAMA · doi:10.1001/jama.293.17.2095 · Cited by 1,187
Klotz, L., Zhang, L., Lam, A., Nam, R., Mamedov, A., & Loblaw, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2180 · Cited by 1,074
Self-citationReview of survival analyses published in cancer journals
Altman, D., De Stavola, B., Love, S., & Stepniewska, K. (1995) · British Journal of Cancer · doi:10.1038/bjc.1995.364 · Cited by 438
Active Surveillance for Prostate Cancer: For Whom?
Klotz, L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3134 · Cited by 353
Self-citationRandomized Trial Comparing Two Fractionation Schedules for Patients With Localized Prostate Cancer
Lukka, H., Hayter, C., Julian, J. A., Warde, P., Morris, W. J., Gospodarowicz, M., Levine, M., Sathya, J., Choo, R., Prichard, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.153 · Cited by 349
Vickers, A. J., Savage, C., O'Brien, M. F., & Lilja, H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1685 · Cited by 254
Natural History of Early, Localized Prostate Cancer: A Final Report from Three Decades of Follow-up
Popiolek, M., Rider, J. R., Andrén, O., Andersson, S.-O., Holmberg, L., Adami, H.-O., & Johansson, J.-E. (2013) · European Urology · doi:10.1016/j.eururo.2012.10.002 · Cited by 226
van As, N. J., Norman, A. R., Thomas, K., Khoo, V. S., Thompson, A., Huddart, R. A., Horwich, A., Dearnaley, D. P., & Parker, C. C. (2008) · European Urology · doi:10.1016/j.eururo.2008.02.039 · Cited by 216
Roemeling, S., Roobol, M. J., de Vries, S. H., Wolters, T., Gosselaar, C., van Leenders, G. J. L. H., & Schröder, F. H. (2007) · European Urology · doi:10.1016/j.eururo.2006.11.053 · Cited by 160
Ali, K., Gunnar, A., Jan‐Erik, D., Lilja, H. G., Pär, L., & Jonas, H. (2006) · International Journal of Cancer · doi:10.1002/ijc.22161 · Cited by 157
Kane, C. J., Im, R. D., Amling, C. L., Presti, J. C., Aronson, W. J., Terris, M. K., & Freedland, S. J. (2010) · Urology · doi:10.1016/j.urology.2009.12.073 · Cited by 76
Modeling Prostate Specific Antigen Kinetics in Patients on Active Surveillance
Zhang, L., Loblaw, A., & Klotz, L. H. (2006) · The Journal of Urology · doi:10.1016/j.juro.2006.06.103 · Cited by 63
Self-citation
Cited by
10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer
Hamdy, F. C., Donovan, J. L., Lane, J. A., Mason, M., Metcalfe, C., Holding, P., Davis, M., Peters, T. J., Turner, E. L., Martin, R. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606220 · Cited by 2,640
The Diagnosis and Treatment of Prostate Cancer: A Review
Litwin, M. S., & Tan, H.-J. (2017) · JAMA · doi:10.1001/jama.2017.7248 · Cited by 1,435
Gillessen, S., Attard, G., Beer, T. M., Beltran, H., Bossi, A., Bristow, R., Carver, B., Castellano, D., Chung, B. H., Clarke, N., et al. (2018) · European Urology · doi:10.1016/j.eururo.2017.06.002 · Cited by 642
Follow-up of Prostatectomy versus Observation for Early Prostate Cancer
Wilt, T. J., Jones, K. M., Barry, M. J., Andriole, G. L., Culkin, D., Wheeler, T., Aronson, W. J., & Brawer, M. K. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615869 · Cited by 623
Genomic hallmarks of localized, non-indolent prostate cancer
Fraser, M., Sabelnykova, V. Y., Yamaguchi, T. N., Heisler, L. E., Livingstone, J., Huang, V., Shiah, Y.-J., Yousif, F., Lin, X., Masella, A. P., et al. (2017) · Nature · doi:10.1038/nature20788 · Cited by 600
Metadata
- Authors
- Klotz, L., Vesprini, D., Sethukavalan, P., Jethava, V., Zhang, L., Jain, S., Yamamoto, T., Mamedov, A., & Loblaw, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-01-20
- Volume
- 33
- Issue
- 3
- Pages
- 272-277
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106869018
- Cited by
- 1,221
- References
- 13
- FWCI
- 101.05
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.